Products

EyeCALIBUR+

Total Control of your Monitor

eyecalibur.com Utilities / System Utilities

Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
$24.99/mo
Higher than 90% of peersNiche median $9/mo
Creators
Elay Rodriguez
No social account linked
Launched
5mo ago
2026-06-30 · Est.

Traffic

Last 12 months
Monthly visitsData through Oct 2026
Events1 marketing move

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Product HuntLaunch

    Bypass Windows monitor limits & unlock advanced GPU control.

    Jun 30 · 5mo agoLaunch page

Traffic sources

Oct 2026

Traffic breakdown

Channels

No data yet

Countries

No data yet

Search

Domain authority —Domain registered 2026-05-12

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

Monthly Subscription
Unknown
Founder's License (Lifetime)
$24.99/once
Annual Subscription
Unknown

Trial: None · 1 paid tier ($24.99) · Observed 2026-11-06 · Source page

Entry price $24.99/mo, Higher than 90% of peers; “System Utilities” median is $9/mo.View pricing benchmark

Website snapshots

Indexed 2026-06-30

Key pages

Desktop & mobile archive
eyecalibur.com/en/ Snapshot 2026-11-06

Questions & evidence

How much does EyeCALIBUR+ cost?
Monthly Subscription: Unknown; Founder's License (Lifetime): $24.99/once; Annual Subscription: Unknown. Observed 2026-11-06. Check the source for current billing terms, usage limits and taxes.Source
How much website traffic does EyeCALIBUR+ get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is EyeCALIBUR+ and what platforms does it support?
EyeCALIBUR+ is catalogued under System Utilities: Total Control of your Monitor. Supported platforms: Web.

Related products in this category

Utilities / System Utilities

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.